Companies › Inventage Lab.
3 active drug programs in 3 registered trials: 3 Phase 1; Neurology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IVL3003 Donepezil long-acting injection | ACHE | Phase 1 | Alzheimer Disease | – |
| IVL3004 Opioid receptor antagonist (long-acting injection) | OPRM1 | Phase 1 | Opioid Dependence | – |
| IVL4002 Opioid receptor antagonist (long-acting injection) | OPRM1 | Phase 1 | Opioid Dependence | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05345509 | IVL3003 | Phase 1 | Alzheimer Disease | Neurology | Nov 2025 |
| NCT05620940 | IVL3004 | Phase 1 | Opioid Dependence | Neurology | Dec 2025 |
| NCT05620940 | IVL4002 | Phase 1 | Opioid Dependence | Neurology | Dec 2025 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.